Products

Invivyd

On a mission to rapidly and continually deliver antibody-based therapies that keep pace with the evolving viral threats

invivyd.com Source★ 19Apache-2.0Industry Software / Life Sciences & Biotech

AI Benchmark
Desktop
Mobile
Monthly visits
10.3K
Down8.9%MoMOct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Free
No monthly subscription pricing
Creators
Invivyd
@invivyd· 2,888 followers
Launched
4y ago
2022-08-05 · Est.

Traffic

Monthly visitsData through Oct 2026
Events18 changes · 1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Invivyd reports Q3 2026 financial resultsReferrals & Backlinks

    Invivyd published a release reporting third quarter 2026 financial results and recent business highlights.

    Nov 16 · YesterdayX Post

    At the time: 10.3K visits/mo18 concurrent moves
  • New product launchLaunch

    Aug 5, 2022 · 4y agoWebsite

Open Source & Self-Hosting

GitHub · MCP / Skill
Last commit 2026-10-30
GitHub Stars
★ 19
Forks
12
License
Apache-2.0
Primary language
JavaScript

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Organic Search32%
  • Direct30%
  • Display Ads10%
  • Social9%
  • Other19%

Countries

  • United States77%
  • India14%
  • United Kingdom10%

Search

Domain authority —Domain registered 2022-08-05

KeywordMonthly volume
invivyd1,490
operando1,350
invivyd flintlock200
covid inuvid140
adagio covid70

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2026-11-04

Key pages

Weekly snapshots
www.invivyd.com/ Snapshot 2026-11-05

Changes

  1. Nov 1 · 16d ago

    Adopted technology: Apple iCloud MailFeatures

    —→Apple iCloud Mail

    At the time: 10.3K visits/mo18 concurrent moves
  2. Nov 1 · 16d ago

    Adopted technology: Backbone.jsFeatures

    —→Backbone.js

    At the time: 10.3K visits/mo18 concurrent moves
  3. Nov 1 · 16d ago

    Removed technology: CloudflareFeatures

    Cloudflare→—

    At the time: 10.3K visits/mo18 concurrent moves
  4. Nov 1 · 16d ago

    Removed technology: Cloudflare Bot ManagementFeatures

    Cloudflare Bot Management→—

    At the time: 10.3K visits/mo18 concurrent moves
  5. Nov 1 · 16d ago

    Adopted technology: FastlyFeatures

    —→Fastly

    At the time: 10.3K visits/mo18 concurrent moves
  6. Nov 1 · 16d ago

    Removed technology: Google AnalyticsFeatures

    Google Analytics→—

    At the time: 10.3K visits/mo18 concurrent moves

Design

First-screen visual analysis & :root CSS

Editorial (Light canvas, airy density) featuring split copy & visual layout and illustration / character art visuals.

First-screen preview · click to zoom

First-screen pitch & conversion flow

“EVOLVED IMMUNITY. INTELLIGENTLY DESIGNED.”

Split Copy & Visual hero structure paired with start free / sign up CTA and no explicit trust bar.

Conversion path: Split Copy & Visual + Illustration / Character Art → Start Free / Sign Up

Palette · click to copy

5-D design score8.1 / 10
Typography
9.0
Color & Contrast
8.0
Layout & Spacing
8.0
Craft & Polish
8.0
Distinctiveness
7.0

Structure

Fonts
Playfair Display / Arial
Primary visual
Illustration / Character Art
Conversion CTA
Start Free / Sign Up
Social proof
No Explicit Trust Bar
Navigation
Minimal Logo + Action
Theme & density
Light · Airy
Corners & depth
Small Radius · Hairline borders
Preview full AI design brief (includes :root CSS variables & layout rules)Style tokens only; never copy brand names, logos, copy, or images
# Design Brief: Editorial

Oversized serif headlines, narrow reading columns, and magazine-inspired grid layouts.

## Design Tokens

```css
:root {
  --background: #fbf9f2;
  --surface: #f5f1e8;
  --foreground: #092547;
  --muted-foreground: #34485e;
  --accent: #182c59;
  --radius: 4px;
  --font-heading: "Playfair Display", ui-sans-serif, system-ui, sans-serif;
  --font-body: "Arial", ui-sans-serif, system-ui, sans-serif;
}
```

Color area ratio: Background #FBF9F2 (~84%) · Surface #F5F1E8 (~2%) · Text #092547 (~8%) · Muted Text #34485E (~3%) · Accent #182C59 (~3%). Background and surface dominate the canvas; reserve the accent color for primary buttons and active states.

## Layout & Conversion Structure

- Hero layout: Split Copy & Visual
- Navigation: Minimal Logo + Action
- Theme & density: Light · Airy
- Border radius & elevation: Small Radius; no drop shadows—separate layers with hairline borders and whitespace
- Primary visual medium: Illustration / Character Art
- Conversion CTA: Start Free / Sign Up
- Headline hook: Brand Manifesto & Curiosity
- Hero components: Custom Illustration
- Spatial layout notes: Split Copy & Visual hero structure paired with start free / sign up CTA and no explicit trust bar.
- Visual summary: Editorial (Light canvas, airy density) featuring split copy & visual layout and illustration / character art visuals.

## Avoid

- Generic SaaS hero templates
- Cramped multi-column feature grids
- Neon cyber accents

Implement the UI following the design tokens and layout specifications above: use only these color variables, and reserve the accent color strictly for primary actions and active states. Adopt only this visual style—never copy any reference product’s brand name, logo, copy, or imagery.

Questions & evidence

How much website traffic does Invivyd get?
Vaneform estimates 10.3K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Invivyd and what platforms does it support?
Invivyd is catalogued under Life Sciences & Biotech: On a mission to rapidly and continually deliver antibody-based therapies that keep pace with the evolving viral threats. Supported platforms: Web.
Is Invivyd open source?
Invivyd has a public repository (https://github.com/newrelic/newrelic-browser-agent) under the Apache-2.0 license, recording 19 GitHub stars.Source

Related products in this category

Industry Software / Life Sciences & Biotech

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.